ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1445	National Cancer Institute	Html	en	Oral Complications of Chemotherapy and Head/Neck Radiation (PDQ®)–Health Professional Version	Expert-reviewed information summary about oral complications, such as mucositis and salivary gland dysfunction, that occur in cancer patients treated with chemotherapy or radiation therapy to the head and neck.	Oral Mucositis section 0.646528 oral lesions 0.713241 permanent oral complications 0.655143 especially oral mucositis 0.68535 hematopoietic stem cell 0.672562 severe oral mucositis 0.704955 normal oral function. 0.655722 oral infection 0.648431 oral anatomic structures 0.655446 cancer therapy 0.661822 oral pain 0.661419 oral tissues 0.687688 oral management 0.671998 oral mucositis 0.976928 acute oral complications 0.672602 oral complications 0.869367 comprehensive oral care 0.65304 cancer patients 0.684573 oral manifestations 0.663979 Poor oral health 0.644837 oral health 0.672192 local oral infections 0.645116 oral mucosal inflammation 0.655414 necessary oral care 0.650666 oral mucositis index 0.679834	severe oral morbidity 0.658041 item oral mucositis 0.6536 oral mucosa 0.692735 oral care 0.722741 oral mucosal changes 0.646052 oral mucositis guidelines 0.662614 radiation-induced oral mucositis 0.65347 oral mucosal tissues 0.663688 Severe oral toxicities 0.662231 ulcerative oral mucositis 0.758526 chemotherapy-induced oral mucositis 0.687692 common oral complications 0.674757 oral mucosal healing 0.660629 comprehensive oral hygiene 0.655656 oral hygiene 0.74644 oral status 0.661747 oral mucosal integrity 0.669711 nonmedicated oral care 0.646962 acute oral GVHD 0.644918 oral mucosal toxicity 0.664745 oral toxicities 0.662473 oral cavity 0.705394 cancer 0.687828 oral disease 0.662382	CLICK HERE
1480	National Cancer Institute	Html	en	Gastric Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of gastric cancer.	median survival 0.63157 Three-year overall survival 0.637349 postoperative chemotherapy 0.607291 evidence 0.599884 S-1 group 0.532476 United States 0.629181 IIIB gastric cancer 0.571507 gastric cancer resection 0.57432 adjuvant chemoradiation therapy 0.846798 trial 0.61074 Postoperative chemoradiation therapy 0.558554 adjuvant combined modality 0.6554 total gastrectomy 0.60297 3-year OS rate 0.544309 3-year OS rates 0.626301 postoperative combined chemoradiation 0.551401 median follow-up 0.535007 therapy versus surgery 0.546551 chemoradiation therapy group 0.623893 significantly higher likelihood 0.622742 postoperative chemoradiation regimen 0.637796 noncardia gastric cancers 0.63288 surgery-only group 0.537222 relapse-free survival rates 0.794523	3-year OS 0.717532 gastroesophageal junction 0.570534 disease-free survival rate 0.550481 gastric cancer 0.998454 progression-free survival 0.57907 patients 0.884826 Neoadjuvant chemoradiation therapy 0.554541 metastatic gastric cancer 0.697572 curative intent 0.539619 significant survival benefit 0.6365 prospective multi-institution phase 0.543154 surgery-alone arm 0.607016 proximal subtotal gastrectomy 0.57677 perioperative chemotherapy group 0.806838 lymph nodes 0.576141 completely resected stage 0.638305 chemoradiation therapy 0.899775 hazard ratio 0.57654 regional lymph nodes 0.559708 Level 0.600335 chemoradiation therapy versus 0.543268 phase III trial 0.597716 3-year disease-free survival 0.564109	CLICK HERE
1612	National Cancer Institute	Html	en	Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of renal pelvis and ureter transitional cell cancer.	general cancer information 0.245004 treatment 0.36943 cancer treatment 0.274834 new cancer treatments 0.244453 NCI-supported cancer 0.252295 cancer cells 0.305937 cancer spreads 0.254859 body 0.283889 diagnose transitional cell 0.268084 Cancer Information Service 0.245843 PDQ cancer information 0.2892 Recurrent transitional cell 0.259741 segmental resection 0.252407 kidney 0.248946 clinical trial search 0.276195 treatment clinical trials 0.260027 National Cancer Institute 0.300743 clinical trials 0.500017 Ureter Treatment 0.280286 metastatic transitional cell 0.241447 PDQ Transitional Cell 0.249302 cancer information summary 0.272322 clinical trial 0.418117 new treatment 0.269914	breast cancer prevention 0.240544 renal cell cancer 0.301024 ureter 0.545878 patients 0.265691 Blood. The cancer 0.243945 Cell Cancer Treatment 0.266901 PDQ summary 0.241392 treatment clinical trial 0.245285 kidney cancer 0.240494 NCI PDQ cancer 0.250983 cancer research process 0.24139 cancer clinical trials 0.286739 tests 0.24917 stage 0.247801 certain pain medicines 0.268283 tumor 0.244567 treatment options 0.255801 cancer information summaries 0.244613 Treatment Editorial Board 0.244593 comprehensive cancer information 0.244987 renal pelvis 0.969529 standard treatment 0.251972 General information 0.241791	CLICK HERE
1719	National Cancer Institute	Html	en	Sentinel Lymph Node Biopsy	A fact sheet that describes the sentinel lymph node biopsy procedure and details two clinical trials evaluating the effectiveness of this procedure.	breast cancer cells 0.207523 additional lymph nodes 0.324919 lymph node dissection 0.365902 cancer cells 0.313838 completion lymph node 0.32082 additional lymph node 0.319225 sentinel node 0.255614 clinical trials 0.22069 adjuvant systemic therapy 0.201592 nearby lymph nodes 0.410736 regional lymph node 0.311853 lymph vessels 0.353059 extensive lymph node 0.426951 lymph node removal 0.331582 sentinel lymph nodes 0.328406 external-beam radiation therapy 0.223044 positive sentinel lymph 0.331906	lymph node biopsy 0.364124 sentinel lymph node 0.877175 breast cancer 0.260519 negative axillary lymph 0.276414 fewer lymph nodes 0.321344 multiple lymph nodes 0.309038 SLNB 0.244263 lymph node involvement 0.373283 lymph fluid 0.290316 axillary lymph node 0.386593 lymph nodes 0.832406 additional nearby lymph 0.283578 lymph node 0.99204 lymph node surgery 0.535704 regional lymph nodes 0.405136 cancer 0.32073 lymph node metastasis 0.429092	CLICK HERE
1747	National Cancer Institute	Html	en	Asbestos Exposure and Cancer Risk	A fact sheet about asbestos, asbestos-related diseases, and who to contact for more information.	Asbestos Ombudsman 0.460839 EPA state asbestos 0.434096 U.S. Consumer Product 0.316535 longer exposure time 0.297627 previous exposure 0.27831 asbestos textiles 0.432289 asbestos causes 0.436856 U.S. Department 0.329349 children’s exposure 0.28171 lung cancer 0.280063 asbestos programs 0.405413 asbestos minerals 0.467011 asbestos removal workers 0.468852 Asbestos School Hazard 0.419561 health care providers 0.290173 asbestos-related diseases 0.348349 health hazards 0.295432 human health effects 0.27966 asbestos exposure increase 0.500132 asbestos mines 0.425258 serpentine asbestos 0.481061 asbestos mining 0.432341 Asbestos page 0.442685 Federal agency 0.290215	Environmental Protection Agency 0.377868 OSHA’s Asbestos 0.42031 health effects 0.305637 Preventing Asbestos Exposure 0.47948 Product Safety Commission 0.317357 asbestos 0.915525 asbestos fibers 0.648932 asbestos exposure 0.842565 U.S. Environmental Protection 0.377874 heavier exposure 0.277348 Occupational Safety 0.288197 exposure history 0.275525 asbestos products 0.436695 amphibole asbestos 0.479754 Asbestos Hazard Emergency 0.41964 asbestos-related disease 0.298672 tiny asbestos fibers 0.468171 Health Administration 0.283037 occupational asbestos exposure 0.500171 Consumer Product Safety 0.316531 health 0.344549 Chrysotile asbestos 0.460267 information 0.278169 risk 0.275773	CLICK HERE
1822	National Cancer Institute	Html	es	Tratamiento del linfoma no Hodgkin infantil (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del linfoma no Hodgkin infantil.	LNH sobrevivirán 0.259398 Zimmermann M 0.292078 Pediatric Non-Hodgkin Lymphoma 0.307431 with b-cell 0.245734 células t 0.360685 large cell lymphoma 0.592792 large b-cell lymphoma 0.310638 Burkitt lymphoma 0.390944 anaplastic large-cell lymphoma 0.391142 B-cell lymphoma treated 0.259053 Gerrard M 0.253938 Burkitt's lymphoma 0.311811 Non-Hodgkin Lymphoma Staging 0.255329 linfoma folicular tipo 0.251963 childhood t-cell lymphoblastic 0.240771 Leuk Lymphoma 0.317156 Perkins SL 0.288471 childhood cancer 0.239116 or relapsed lymphoma 0.247628 malignant lymphoma 0.246238 Sposto R 0.298634 Non-Hodgkin Lymphoma Response 0.260692 patients with lymphoma 0.260427 group study 0.273614 estadio iv 0.240422	Cairo MS 0.242979 Pediatr Blood Cancer 0.510662 tipo burkitt células 0.244366 Cancer Group Study 0.240733 lymphoblastic lymphoma 0.400773 Clin Oncol 0.804352 B-cell non-Hodgkin 0.317262 sistema nervioso central 0.275043 childhood b-cell 0.244175 lymphoma kinase-positive 0.244682 non-hodgkin lymphoma 0.692526 Children's Cancer Group 0.319924 lymphoma clinical trials 0.248853 b-cell lymphoma 0.27822 tipo burkitt 0.265416 non-hodgkin's lymphoma 0.96423 mediastinal b-cell lymphoma 0.256031 group report 0.255665 children's oncology group 0.421119 anaplastic large cell 0.389279 Burkitt's lymphoma from 0.271141 lymphoma with tumor 0.259565 células b 0.2577 Burkhardt B 0.329473	CLICK HERE
1871	National Cancer Institute	Html	es	Tratamiento del carcinoma de sitio primario desconocido (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del carcinoma de sitio primario desconocido.	cáncer epitelial versus 0.404134 Greco FA 0.432795 unknown primary tumours 0.414817 cisplatin-based combination chemotherapy 0.404363 unknown primary site 0.721557 Pavlidis N 0.405224 Breast carcinoma presenting 0.411406 unknown primary origin 0.450607 Hainsworth JD 0.442528 Metastatic malignant melanoma 0.405856 Cancer Res 0.404192 Radiat Oncol Biol 0.414855 neuroendocrine carcinoma 0.415368 Natl Cancer Inst 0.417117 poorly differentiated 0.438667 Melanoma from unknown 0.410685 serous papillary carcinoma 0.405287 patients with 0.456873 gene expression profiling 0.404698 unknown primary carcinoma 0.451216 carcinoma nasofaríngeo 0.409399 poorly differentiated carcinoma 0.41977 cervical lymph 0.404293 patients with unknown 0.4336 Rodriguez E 0.405003	presenting as axillary 0.404521 metastases from unknown 0.428245 Unknown primary melanoma 0.416245 Abbruzzese MC 0.404845 Curr Probl Cancer 0.404442 primary neoplasm 0.406005 or undiscovered primary 0.406863 from unknown primary 0.455678 primary tumor site 0.417993 Surg Oncol 0.405079 PDQ Tratamiento 0.416061 Intern Med 0.413673 nasopharyngeal carcinoma 0.405469 Clin Oncol 0.44391 Johnson DH 0.404766 unknown primary 0.993061 Oncol Biol Phys 0.415244 with unknown primary 0.46599 metastatic adenocarcinomas 0.408539 unknown primary tumor 0.442645 germ cell tumors 0.405207 carcinoma presenting as 0.411228 occult primary carcinoma 0.410287 cancer incidence 0.406991	CLICK HERE
2063	National Cancer Institute	Html	es	Radón y cáncer	Hoja informativa acerca del radón, un gas radiactivo sin olor, y su posible asociación con el cáncer, y cómo realizar pruebas de detección del radón en el hogar.	residential radon case-control 0.38371 Health Risks 0.326257 residential radon 0.683536 elevada exposición 0.322129 American case-control studies 0.325499 Kansas State University 0.319808 lung cancer 0.82038 largo plazo 0.437964 Hill D 0.332319 Scandinavian Journal 0.348044 persons with lung 0.339213 Danish study 0.316865 Environmental Epidemiology 0.320216 Darby S 0.336246 collaborative analysis 0.317051 Environmental Health 0.355768 pequeñas partículas 0.315096 mundo inhala radón 0.518177 Lubin JH 0.346614 combined analysis 0.316876 Estados Unidos 0.584661 likely carcinogen 0.314203 Family From Radon 0.368415 elementos químicos uranio 0.332786 PubMed Abstract 0.939015	Field RW 0.336674 altas concentraciones 0.370467 Cancer Journal 0.333846 Environmental Protection Agency 0.326738 National Radon Hotline 0.369701 Health Effects 0.325858 radón causa 0.50069 Public Health 0.325273 concentración promedio 0.346248 epidemiologic studies 0.342525 disponibles pruebas 0.317342 Exposure Analysis 0.331287 Health Physics 0.355359 BEIR VI 0.314333 gas radón 0.662121 Protecting Yourself 0.31429 corto plazo 0.315556 Residential radon gas 0.389098 risk among german 0.327785 persons without lung 0.339772 única forma 0.341742 Samet JM 0.31548 Retrieved October 0.315338 Zielinski JM 0.315284	CLICK HERE
3885	National Cancer Institute	Html	en	Recurrent Cancer: When Cancer Comes Back	Cancer can recur when treatment doesn’t fully remove or destroy all the cancer cells. Learn about the different types of recurrence and how recurrent cancer is restaged and treated.	childhood cancers 0.476868 Distant recurrence 0.50571 original cancer 0.564629 sadness 0.421168 metastatic cancer 0.487966 type 0.513612 follow-up tests 0.479719 body 0.434324 anger 0.419198 treatments 0.459728 new stage 0.530501 new type 0.47242 before—experience 0.42036 fear 0.418153 distant place 0.475453 tissues 0.43928 shock 0.418728 diagnosis 0.431005 imaging procedures 0.478142 history 0.416978 recurrence 0.563784 different types 0.481078 recurrent cancer 0.74671 effects 0.417676 tests 0.513085	PDQ® cancer treatment 0.538695 lymph nodes 0.48537 New drugs 0.480401 chronic disease 0.48607 doctors 0.43873 new assessment 0.472279 treatment 0.554752 primary cancer 0.524976 Local recurrence 0.508295 methods 0.41771 cancer cells 0.53799 lab tests 0.472499 metastasis 0.419606 Regional recurrence 0.507489 cases 0.417606 colon cancer 0.521555 original stage 0.470341 people 0.436769 doctor 0.449906 tumors 0.41688 cancer 0.972673 new cancer 0.482803 time 0.417134 small number 0.481583	CLICK HERE
16812	National Cancer Institute	Html	es	Cartílago (bovino y de tiburón) (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos sobre el uso de cartílago bovino y de tiburón como tratamiento para personas con cáncer. Nota: la información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.	MIA Shark Powder 0.309592 libera productos 0.304775 Centro Nacional 0.308058 New Hampshire Avenue 0.30568 Drug Administration 0.303513 NCI Best Case 0.309322 vía oral 0.453913 datos bibliográficos pubmed 0.30595 células llamadas condrocitos 0.314707 siguientes preguntas 0.30389 numerosos productos 0.303672 cartílago bovino catrix 0.352078 National Cancer Institute 0.306865 siguientes riesgos 0.304822 Instituto Nacional 0.331095 Salud Complementaria 0.311787 Visuals Online 0.304093 complementarias revisa 0.305499	Physician Data Query 0.323561 Estados Unidos 0.439543 PDQ Cartílago 0.345303 siguientes estudios 0.31921 libre uso 0.304173 cartílago bovino 0.858349 página manejo 0.303836 tiburón quizás 0.3125 numerosos estudios 0.308556 ¿El tratamiento 0.308146 tiburón llamada ae-941 0.314557 siguientes datos 0.30538 ¿Los beneficios 0.303518 juntos cam 0.30337 Series Program 0.303472 vasos sanguíneos 0.95448 medicina complementaria 0.461353	CLICK HERE